{
  "id": 17872639,
  "title": "RA Capital Management sells $9.13M in Lenz Therapeutics shares",
  "url": "https://urgent.news/2026/11/02/ra-capital-management-sells-9-13m-in-lenz-therapeutics-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-02T23:16:12.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/ra-capital-management-sells-913m-in-lenz-therapeutics-shares-93CH-4993186"
  },
  "original_language": "en",
  "account": "RA Capital Management, L.P., a director and 10% owner of LENZ Therapeutics, Inc., announced on October 29, 2026, the sale of common stock amounting to approximately $9,134,778. The company owned 2,718,684 shares, which were sold in three separate transactions at a weighted average price of $3.36 per share, ranging from $3.16 to $3.58. The largest transaction was the sale of 2,159,516 shares, totaling about $7,256,094. Following the sale, RA Capital Management, L.P. indirectly owned 1,159,823 shares through RA Capital Healthcare Fund, L.P., 242,757 shares through RA Capital Nexus Fund II, L.P., and 57,559 shares through a separately managed account. LENZ shares had declined by nearly 90% over the past year, currently trading near its 52-week low of $2.80. Despite the stock's decline, the presbyopia eye drop, VIZZ, demonstrated growth, with revenue increasing by more than 50% sequentially to $2.6 million and prescriptions rising to 38,000. Lenz Therapeutics adjusted its price target from $38 to $16, with a Buy rating maintained.",
  "summary": null,
  "key_points": [
    "RA Capital Management sold $9.13M in LENZ Therapeutics shares on October 29, 2026",
    "The company owned 2,718,684 shares, sold in three transactions at $3.36 average price",
    "LENZ shares declined 90% year-over-year, VIZZ revenue grew 50% sequentially"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}